false 0001703057 00-0000000 0001703057 2022-06-29 2022-06-29

 

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________________________________________

FORM 8-K

__________________________________________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 29, 2022

__________________________________________________

ABCELLERA BIOLOGICS INC.

(Exact name of registrant as specified in its charter)

__________________________________________________

British Columbia

 

001-39781

 

Not Applicable

(State or other jurisdiction of incorporation)

 

(Commission File Number)

 

(IRS Employer Identification Number)

 

2215 Yukon Street

Vancouver, BC

 

 

 

 V5Y 0A1

(Address of registrant’s principal executive office)

 

 

 

(Zip code)

(604) 559-9005

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

__________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common shares

ABCL

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company    

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 

 

 


Item 7.01 Other Items.

 

On June 29, 2022, AbCellera Biologics Inc. (the “Company”), issued a press release titled “Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options”. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

 

 

 

 

 

 

 

 

 

Exhibit

No.

 

Description

99.1

 

Press Release issued by AbCellera Biologics Inc. on June 29, 2022.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)


 



 


 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 

 

 

 

 

 

 

 

 

 

 

 

Date: June 30, 2022

ABCELLERA BIOLOGICS INC.

 

 

 

 

By:

 

/s/ Carl L. G. Hansen

 

 

 

Carl L. G. Hansen, Ph.D.

 

 

 

Chief Executive Officer and Director

(Principal Executive Officer)

 

 

AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more AbCellera Biologics Charts.
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more AbCellera Biologics Charts.